Your browser doesn't support javascript.
loading
Research Progress of Antitumor Pharmacovigilance / 中国肺癌杂志
Zhongguo fei'ai zazhi (Online) ; Zhongguo fei'ai zazhi (Online);(12): 541-545, 2022.
Article in Zh | WPRIM | ID: wpr-939744
Responsible library: WPRO
ABSTRACT
In 2019, Drug Administration Law of China was first time proposed that the country should establish pharmacovigilance system. In 2021, the first Pharmacovigilance Quality Management Standard of China was released. The proposal and implementation of pharmacovigilance were the initial stage in China, and it needed to improve the aspects of pharmacovigilance include institution, monitoring mechanism and database construction. The number of new diagnosed cancer patients in China ranked first in the world. In recent years, the marketing speed of novel antitumor drugs was accelerated, and there were many clinical trials. Therefore, antitumor pharmacovigilance was imperative. In this article, we summarized pharmacovigilance of the origin, clinical practice objectives, procedures, methods. We described the difficulties in antitumor pharmacovigilance and current characteristics of pharmacovigilance in China, aiming to provide reference for the development of antitumor pharmacovigilance.
.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: China / Pharmacovigilance / Lung Neoplasms Limits: Humans Country/Region as subject: Asia Language: Zh Journal: Zhongguo fei'ai zazhi (Online) Year: 2022 Type: Article
Full text: 1 Index: WPRIM Main subject: China / Pharmacovigilance / Lung Neoplasms Limits: Humans Country/Region as subject: Asia Language: Zh Journal: Zhongguo fei'ai zazhi (Online) Year: 2022 Type: Article